Clinical Trials Logo

Colitis, Ulcerative clinical trials

View clinical trials related to Colitis, Ulcerative.

Filter by:

NCT ID: NCT04706793 Completed - Ulcerative Colitis Clinical Trials

Oral Etrasimod Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis in Adult Japanese Participants (ELEVATE UC 40 JAPAN)

Start date: December 25, 2020
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine whether oral etrasimod is a safe and effective treatment in adult Japanese participants with moderately to severely active ulcerative colitis (UC). This study is an extension of study APD334-302 (NCT03996369). Participants will continue with the same blinded treatment assigned in Study APD334-302 for a total treatment duration of 52 weeks (12 weeks in Study APD334-302 plus 40 weeks in Study APD334-308).

NCT ID: NCT04700449 Completed - Clinical trials for Moderate to Severe Ulcerative Colitis

A Study Assessing the Efficacy and Safety of CBP-307 in Subjects With Moderate to Severe Ulcerative Colitis (UC)

Start date: February 27, 2019
Phase: Phase 2
Study type: Interventional

This study will evaluate the efficacy and safety of CBP-307 in subjects with moderate to severe ulcerative colitis (UC).

NCT ID: NCT04691232 Completed - Ulcerative Colitis Clinical Trials

Autologous Ex Vivo Expanded Regulatory T Cells in Ulcerative Colitis

Start date: February 22, 2021
Phase: Phase 1
Study type: Interventional

Together with Crohn's disease (CD), ulcerative colitis (UC) is one of the major forms of inflammatory bowel diseases (IBD).Currently, no curative therapy is available, since the pathophysiology of this disease is incompletely understood (1-3) and clinical practice demonstrates that current therapies induce remission in subgroups of patients only. Scientific evidence suggests that colitogenic immune responses can be controlled by increasing the number of circulating regulatory T cells (Treg) (4). The production of large numbers of autologous Treg is possible by isolation of CD25+ cells from the whole blood of a patient and subsequent ex vivo expansion in the presence of the immunomodulatory drug rapamycin, Interleukin-2 (IL-2) and CD3/CD28 expander beads (5). ER-TREG 01 is a single-center, open-label, fast-track phase I dose-escalation study designed to assess the safety profile and maximal tolerated dose (MTD) of a single infusion of ex vivo expanded autologous Treg in patients with active ulcerative colitis.

NCT ID: NCT04650867 Completed - Ulcerative Colitis Clinical Trials

Non Invasive Characterization of Pediatric Inflammatory Bowel Diseases Using Multispectral Optoacoustic Tomography

PED_MSOT_IBD
Start date: March 22, 2021
Phase:
Study type: Observational

Monocentric, prospective observational study to assess bowel inflammation in children with chronic inflammatory bowel disease (IBD) using multispectral optoacoustic tomography (MSOT).

NCT ID: NCT04597905 Completed - Crohn Disease Clinical Trials

Paricipant Preferences in the Treatment of Inflammatory Bowel Disease (IBD) in Europe

Start date: October 21, 2020
Phase:
Study type: Observational

The purpose of this survey is to describe Crohn's disease (CD) participants' as well as ulcerative colitis (UC) participants' preferences towards the attributes of treatment with advanced therapies for IBD, including safety and efficacy profiles, frequency and route of administration (RoA) in a real-world setting.

NCT ID: NCT04596293 Completed - Ulcerative Colitis Clinical Trials

Efficacy and Safety of Orally Administered BBT-401-1S in Subjects With Ulcerative Colitis

Start date: June 11, 2021
Phase: Phase 2
Study type: Interventional

This is a randomised, double-blind, placebo-controlled, proof of clinical principle study to explore the efficacy and safety of orally administered BBT-401-1S in subjects with ulcerative colitis.

NCT ID: NCT04577794 Completed - Ulcerative Colitis Clinical Trials

A Study Evaluating the Effects of GLPG3970 Given as an Oral Treatment for 6 Weeks in Adults With Ulcerative Colitis

SEA TURTLE
Start date: October 5, 2020
Phase: Phase 2
Study type: Interventional

The primary objective of this study was to evaluate the effect of GLPG3970 compared to placebo on the signs and symptoms of Ulcerative Colitis (UC) in participants with moderately to severely active UC.

NCT ID: NCT04567628 Completed - Crohn Disease Clinical Trials

Study of Relationship Between Vedolizumab Therapeutic Drug Monitoring, Biomarkers of Inflammation and Clinical Outcomes

VEDO TDM RWE
Start date: October 5, 2020
Phase:
Study type: Observational

The purpose of this study is to determine if a relationship exists between Week 6 vedolizumab therapeutic drug monitoring (TDM) and Week 30 Faecal calprotectin (FCP).

NCT ID: NCT04564638 Completed - Ulcerative Colitis Clinical Trials

Long-term Outcome of Patients With Acute Ulcerative Colitis After First Course of Intravenous Corticosteroids

Start date: March 1, 2015
Phase:
Study type: Observational [Patient Registry]

All episodes of patients with acute UC admitted to Tampere University Hospital and treated with intravenous corticosteroids between January 2007 and January 2016 were identified from patient records and reviewed. The risks for colectomy and for continuous use of corticosteroids were evaluated. Predictive factors were analysed.

NCT ID: NCT04508413 Completed - Ulcerative Colitis Clinical Trials

A Clinical Study to Assess the Effects of KB295 in Patients With Ulcerative Colitis (UC) on Gut Microbiota Structure and Function

Start date: August 12, 2020
Phase: N/A
Study type: Interventional

This exploratory, open-label clinical study aims to explore the effects of KB295, a novel glycan, on adult patients with ulcerative colitis (UC) presenting with mild-to-moderate UC symptoms